Premium
Inflammatory factor‐based prognostic risk stratification for patients with metastatic castration‐resistant prostate cancer treated with docetaxel
Author(s) -
Shi Xinyu,
Fan Junjie,
Pei Xinqi,
Wang Yuzhao,
Guo Guodong,
Yang Tao,
Wang Xinyang,
He Dalin,
Li Lei
Publication year - 2021
Publication title -
andrologia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.633
H-Index - 59
eISSN - 1439-0272
pISSN - 0303-4569
DOI - 10.1111/and.14064
Subject(s) - medicine , docetaxel , prostate cancer , proportional hazards model , oncology , neutrophil to lymphocyte ratio , androgen deprivation therapy , chemotherapy , multivariate analysis , survival analysis , cancer , lymphocyte
To develop a simple inflammatory factor‐based prognostic risk stratification system for patients with metastatic castration‐resistant prostate cancer (mCRPC) receiving docetaxel as the initial treatment, we reviewed the data of 399 consecutive patients who received first‐line docetaxel chemotherapy between January 2013 and June 2019 retrospectively. The optimal cut‐off values for the neutrophil‐to‐lymphocyte ratio (NLR) and platelet‐to‐lymphocyte ratio (PLR) in terms of survival were calculated by ROC curves. Patients were stratified into favourable (lower NLR and lower PLR), intermediate (higher NLR and lower PLR, or lower NLR and higher PLR) and poor (higher NLR and higher PLR) groups. Kaplan–Meier curves were drawn to evaluate overall survival (OS) and progression‐free survival (PFS). The ROC curve analysis determined the cut‐offs for the NLR and PLR to be 2.355 and 104.275 respectively. Multivariate Cox regression analysis showed that being in the poor patient group (NLR ≥2.355 and PLR ≥104.275) was an independent prognostic risk factor and Kaplan–Meier curves analysis revealed that respondents with NLR <2.355 and PLR <104.275 had significantly longer OS and PFS. So it can be concluded that concurrently high NLR and PLR values are predictors for poor chemotherapy outcomes after androgen deprivation therapy failure in patients with mCRPC.